| |
N0/M0
|
N+
|
M+
|
|---|
|
n (%)
|
n (%)
|
n (%)
|
|---|
|
VEGF-C+/VEGFR-2+
| | | |
|
Capillaries
|
zone 1
|
20/8 (40)
|
9/6 (67)
|
9/6 (67)
|
|
zone 2
|
16/16 (100)
|
11/11 (100)
|
11/9 (82)
|
|
zone 3
|
18/11 (61)
|
13/11 (85)
|
16/14 (88)
|
|
Small vessels
|
zone 1
|
16/12 (75)
|
11/6 (55)
|
15/8 (53)
|
|
zone 2
|
23/21 (91)
|
16/15 (94)
|
17/14 (82)
|
|
zone 3
|
17/9 (53)
|
14/8 (57)
|
13/7 (54)
|
|
VEGF-D+/VEGFR-2+
| | | |
|
Capillaries
|
zone 1
|
11/10 (91)
|
8/7 (88)
|
9/8 (89)
|
|
zone 2
|
19/19 (100)
|
11/11 (100)
|
15/14 (93)
|
|
zone 3
|
21/15 (71)
|
14/12 (86)
|
12/12 (100)
|
|
Small vessels
|
zone 1
|
10/9 (90)
|
6/4 (67)
|
8/5 (63)
|
|
zone 2
|
27/24 (89)
|
17/16 (94)
|
19/17 (89)
|
|
zone 3
|
26/16 (62)
|
19/11 (58)
|
15/10 (67)
|
|
VEGFR-2+/VEGFR-2
Tyr1175
+
| | | |
|
Capillaries
|
zone 1
|
20/17 (85)
|
14/14 (100)
|
12/10 (83)
|
|
zone 2
|
34/31 (91)
|
21/19 (90)
|
18/15 (83)
|
|
zone 3
|
22/22 (100)
|
18/17 (94)
|
19/18 (95)
|
|
Small vessels
|
zone 1
|
13/10 (77)
|
8/8 (100)
|
11/9 (82)
|
|
zone 2
|
29/26 (90)
|
20/18 (90)
|
16/14 (88)
|
|
zone 3
|
18/16 (89)
|
12/12 (100)
|
9/8 (89)
|
|
VEGFR-2+/VEGFR-2
Tyr1214
+
| | | |
|
Capillaries
|
zone 1
|
19/18 (95)
|
13/10 (77)
|
14/13 (93)
|
|
zone 2
|
33/32 (97)
|
21/19 (90)
|
21/21 (100)
|
|
zone 3
|
21/21 (100)
|
15/15 (100)
|
21/21 (100)
|
|
Small vessels
|
zone 1
|
15/14 (93)
|
8/6 (75)
|
11/10 (91)
|
|
zone 2
|
27/27 (100)
|
20/19 (95)
|
19/19 (100)
|
|
zone 3
|
17/17 (100)
|
12/11 (92)
|
12/12 (100)
|
- n: total number of ligand positive cases / total number of ligand positive cases with concomitant VEGFR-2 positivity or total number of VEGFR-2 positive cases / total number of VEGFR-2 positive cases with concomitant pVEGFR-2 positivity. There were no significant differences between the groups
